Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinsons Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations Progressing Towards Clinic Ongoing Collaboration with Lonza to Support the Manufacturing of our Pipeline of Novel AAV9-Based Gene Therapy Programs NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. Continue reading →

Anne Pelletier-Cameron, M.D., often jokes to her patients that shes a female plumber of the lower urinary tract. On a more professional note, however, shes a urologist in the Michigan Medicine Department of Urology. In this role, Pelletier-Cameron treats patients with a variety of lower urinary tract symptoms Continue reading →

Parkinsons UK and Alzheimers Research UK have teamed up to help fund a project that will test whether a waste disposal system in the brain could be exploited to help in the understanding and treatment of these diseases, Parkinsons UK announced. The new project, which is expected to take about three years to complete, will focus specifically on the glymphatic system. This system, which was discovered only recently, helps to remove waste products from the brain. Continue reading →

Whether its the smell of cookies baking or Fidos ahem gas, smells have a way of seizing our attention. But when subtle odors interfere with daily living, you may have a condition called hyperosmia. Cleveland Clinic is a non-profit academic medical center Continue reading →

Most people with Gaucher disease (GD) would like to be informed by their health care provider at diagnosis of their risk of developing Parkinsons disease, a survey among U.S. patients shows Continue reading →

New Jersey has one of the highest rates in the nation of Parkinson's disease a neuro-degenerative disorder, typically affecting residents between ages 60 and 70 years old. Continue reading →

AUGUSTA, Ga. (WJBF) Dr. John Morgan is the director of the Movement and Memory Disorder Program at the Medical College of Georgia at Augusta University. Continue reading →

One of the key goals of the Weill NeuroHub is to explore the brains circuitry using the most powerful MRIs available, developed at UC Berkeley. With a $106 million gift from the Weill Family Foundation, UC Berkeley (Berkeley), UC San Francisco (UCSF) and the University of Washington (the UW) have launched the Weill Neurohub, an innovative research network that will forge and nurture new collaborations between neuroscientists and researchers working in an array of other disciplinesincluding engineering, computer science, physics, chemistry, and mathematicsto speed the development of new therapies for diseases and disorders that affect the brain and nervous system Continue reading →

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related psychosis at the upcoming 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting. Webcast Details The live webcast will include a presentation of the results by ACADIA management followed by a KOL panel discussion with live Q&A. Continue reading →

SAN DIEGO, Nov. 12, 2019 /PRNewswire/ --Neurocrine Biosciences, Inc Continue reading →